These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3680562)

  • 1. Pharmacokinetics of nilvadipine in healthy volunteers.
    Terakawa M; Tokuma Y; Shishido A; Noguchi H
    J Clin Pharmacol; 1987 Feb; 27(2):111-7. PubMed ID: 3680562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-dose pharmacokinetics of nilvadipine in healthy volunteers.
    Terakawa M; Tokuma Y; Kuwahara N; Shishido A; Noguchi H
    J Clin Pharmacol; 1988 Apr; 28(4):350-5. PubMed ID: 3392233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of two different meals on bioavailability of nilvadipine in healthy volunteers.
    Terakawa M; Tokuma Y; Shishido A; Yasuda K; Noguchi H
    J Clin Pharmacol; 1987 Apr; 27(4):293-6. PubMed ID: 3680587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nilvadipine: profile of a new calcium antagonist. An overview.
    Rosenthal J
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S92-107. PubMed ID: 7898101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of (+)- and (-)-nilvadipine after oral dosing with racemic (+)-nilvadipine in man.
    Tokuma Y; Fujiwara T; Noguchi H
    Res Commun Chem Pathol Pharmacol; 1987 Aug; 57(2):229-37. PubMed ID: 3659571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of oral dosing rate on the hemodynamic and pharmacokinetic profile on nilvadipine.
    Cheung WK; Sia LL; Woodward DL; Graveline JF; Desjardins RE; Yacobi A; Silber BM
    J Clin Pharmacol; 1988 Nov; 28(11):1001-7. PubMed ID: 3243913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects.
    Saima S; Furuie K; Yoshimoto H; Fukuda J; Hayashi T; Echizen H
    Br J Clin Pharmacol; 2002 Feb; 53(2):203-6. PubMed ID: 11851646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the pharmacokinetic and pharmacodynamic profile of nilvadipine in the dog.
    Wu WH; Henderson BM; Lanc R; Garnes D; Yacobi A; Silber BM
    Drug Metab Dispos; 1988; 16(2):222-7. PubMed ID: 2898337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of nilvadipine after single oral doses in healthy volunteers.
    Cheung WK; Woodward DL; Shin K; Hibberd M; Pearse S; Desjardins RE; Yacobi A; Silber BM
    Int J Clin Pharmacol Res; 1988; 8(5):299-305. PubMed ID: 3229870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of nilvadipine in human plasma by capillary column gas chromatography-negative-ion chemical-ionization mass spectrometry.
    Tokuma Y; Fujiwara T; Noguchi H
    J Chromatogr; 1985 Nov; 345(1):51-8. PubMed ID: 4086588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs.
    Tokuma Y; Sekiguchi M; Niwa T; Noguchi H
    Xenobiotica; 1988 Jan; 18(1):21-8. PubMed ID: 3354229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of nilvadipine.
    von Nieciecki A; Huber HJ; Stanislaus F
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S22-9. PubMed ID: 1283185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of (+)- and (-)-nilvadipine in human plasma using chiral stationary-phase liquid chromatography and gas chromatography-mass spectrometry, and a preliminary pharmacokinetic study in humans.
    Tokuma Y; Fujiwara T; Noguchi H
    J Pharm Sci; 1987 Apr; 76(4):310-3. PubMed ID: 3598890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine.
    Breithaupt-Grögler K; Ungethüm W; Meurer-Witt B; Belz GG
    Eur J Clin Pharmacol; 2001 Jul; 57(4):275-84. PubMed ID: 11549204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amlodipine pharmacokinetics in healthy volunteers.
    Williams DM; Cubeddu LX
    J Clin Pharmacol; 1988 Nov; 28(11):990-4. PubMed ID: 2977393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of KRN4884, a novel K channel opener, on the cardiovascular system in anesthetized dogs: a comparison with levcromakalim, nilvadipine, and nifedipine.
    Izumi H; Jinno Y; Kaneta S; Tanaka Y; Okada Y; Izawa T; Ogawa N
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):189-97. PubMed ID: 7475042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of atherogenesis in cholesterol-fed rabbits treated with nilvadipine, a new vasoselective calcium entry blocker.
    Koibuchi Y; Sakai S; Miura S; Ono T; Shibayama F; Ohtsuka M
    Atherosclerosis; 1989 Oct; 79(2-3):147-55. PubMed ID: 2597224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of nilvadipine, a new dihydropyridine-type calcium antagonist.
    Honerjäger P; Seibel K
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S15-21. PubMed ID: 1283184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina.
    Brogden RN; McTavish D
    Drugs Aging; 1995 Feb; 6(2):150-71. PubMed ID: 7711361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereoselective disposition of nilvadipine, a new dihydropyridine calcium antagonist, in the rat and dog.
    Tokuma Y; Fujiwara T; Niwa T; Hashimoto T; Noguchi H
    Res Commun Chem Pathol Pharmacol; 1989 Feb; 63(2):249-62. PubMed ID: 2711027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.